IP Verse

Methods For The Identification, Evaluation And Treatment Of Patients Having Multiple Myeloma - EP3370729

The patent EP3370729 was granted to Celgene on Sep 27, 2023. The application was originally filed on Nov 4, 2016 under application number EP16810119A. The patent is currently recorded with a legal status of "Revoked".

EP3370729

CELGENE
Application Number
EP16810119A
Filing Date
Nov 4, 2016
Status
Revoked
Nov 8, 2024
Grant Date
Sep 27, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSJun 25, 2024KRAUS & LEDERER PARTGMBBADMISSIBLE

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS4868103
DESCRIPTIONUS5539083
DESCRIPTIONUS5631169
DESCRIPTIONUS7442830
DESCRIPTIONUS7687662
DESCRIPTIONUS8003819
DESCRIPTIONUS8530694
DESCRIPTIONWO0105935
DESCRIPTIONWO2009154737
INTERNATIONAL-SEARCH-REPORTWO2012149419
INTERNATIONAL-SEARCH-REPORTWO2015179443
OPPOSITIONWO2012149419

Non-Patent Literature (NPL) Citations (5) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- MAO XUE-HAN, "MULTIPLE HIGH-RISK CYTOGENETIC ABERRATIONS CONFER A PROGRESSIVELY NEGATIVE IMPACT ON SURVIVALS OF NEWLY DIAGNOSED MYELOMA PATIENTS", EHA LIBRARY, (20190614), XP055743900-
EXAMINATION- JEFFREY R SAWYER ED - ROSEMURGY ALEXANDER, "The prognostic significance of cytogenetics and molecular profiling in multiple myeloma", CANCER GENETICS, ELSEVIER, AMSTERDAM, NL, vol. 204, no. 1, doi:10.1016/J.CANCERGENCYTO.2010.11.002, ISSN 2210-7762, (20101101), pages 3 - 12, (20101102), XP028357759
OPPOSITION- Shaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, Sagar Lonial, Jacob P Laubach, Mehdi Hamadani, A Keith Stewart, Parameswaran Hari, Vivek Roy, Robert Vescio, Jonathan L Kaufman, Deborah Berg, Eileen Liao, Alessandra Di Bacco, Jose Estevam, Neeraj Gupta, Ai-Min Hui, Vincent Rajkumar, Paul G Richardson, "Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study", The Lancet Oncology, Elsevier, (20141201), vol. 15, no. 13, doi:10.1016/S1470-2045(14)71125-8, ISSN 14702045, pages 1503 - 1512, XP055203824
OPPOSITION- Richardson Paul G.; Hofmeister Craig C; Rosenbaum Cara A; Htut Myo; Vesole David H.; Berdeja Jesus; Liedtke Michaela; Chari Ajai; Smith Stephen D; Lebovic Daniel; Berg Deborah; Liao Eileen; Gupta Neeraj; Di Bacco Alessandra; Estevam Jose; Hui Ai-Min; Baz Rachid, "Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data", Blood, American Society of Hematology, US, US , (20131115), vol. 122, no. 21, doi:10.1182/blood.V122.21.535.535, ISSN 0006-4971, page 535, XP086751773
OPPOSITION- Gary Lu, Ramya Muddasani, Robert Z. Orlowski, Lynne V. Abruzzo, Muzaffar H. Qazilbash, M. James You, Yaping Wang, Ming Zhao, Su Chen, Isabella Claudia Glitza, L. Jeffrey Medeiros, "Plasma Cell Enrichment Enhances Detection of High-Risk Cytogenomic Abnormalities by Fluorescence In Situ Hybridization and Improves Risk Stratification of Patients With Plasma Cell Neoplasms", ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, College of American Pathologists, US, US , (20130501), vol. 137, no. 5, doi:10.5858/arpa.2012-0209-OA, ISSN 0003-9985, pages 625 - 631, XP055343053

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents